In Case You Missed It
November 7, 2018
Andrew Bowser
Nov 6, 2018
The challenge of successfully treating infection with the hepatitis C virus (HCV) has been significantly reduced in this era of highly effective direct-acting antiviral (DAA) agents; however, there are still important issues for clinicians to be aware of, according to liver disease expert Mitchell L. Shiffman, MD.
“They're not challenges. You just need to be concerned about them,” Dr. Shiffman said in a presentation at the recent American College of Gastroenterology (ACG) meeting in Philadelphia.
While first- and second-line therapy for HCV is very effective, there are still a small number of DAA treatment failures that can be very challenging to manage, said Dr. Shiffman, liver disease expert at Bon Secours Liver Institute of Richmond, Va.
The challenge of successfully treating infection with the hepatitis C virus (HCV) has been significantly reduced in this era of highly effective direct-acting antiviral (DAA) agents; however, there are still important issues for clinicians to be aware of, according to liver disease expert Mitchell L. Shiffman, MD.
“They're not challenges. You just need to be concerned about them,” Dr. Shiffman said in a presentation at the recent American College of Gastroenterology (ACG) meeting in Philadelphia.
While first- and second-line therapy for HCV is very effective, there are still a small number of DAA treatment failures that can be very challenging to manage, said Dr. Shiffman, liver disease expert at Bon Secours Liver Institute of Richmond, Va.
Other issues that should be on the radar:
Monitoring for chronic hepatitis B reactivation
Treatment of active drug users
Managing patients with end-stage renal disease
Read on to learn more about these key issues and comments on each Dr. Shiffman made at ACG.
No comments:
Post a Comment